Granisetron Hydrochloride Injection

Pharmacological action: This product is a highly selective 5-HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. Factors such as radiotherapy, chemotherapy and surgical operations can cause enterochromaffin cells to release 5-HT, and 5-HT can activate the 5-HT3 receptors of the central nervous system or vagus nerve to cause vomiting reflex. The mechanism of this product in controlling nausea and vomiting is to antagonize the 5-HT3 receptors in the central chemoreceptor area and peripheral vagus nerve endings, thereby inhibiting the occurrence of nausea and vomiting. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation. Toxicological studies Reproductive toxicity: The subcutaneous dose of this product is 6 mg/Kg/day (based on body surface area, which is the recommended dose for clinical intravenous administration).

Granisetron Hydrochloride

This product is a colorless clear liquid.

This product is used to prevent or treat nausea and vomiting caused by chemotherapy, and to prevent and treat postoperative nausea and vomiting

The adult dosage is usually 3 mg, diluted with 20-50 ml 5% glucose injection or 0.9% sodium chloride injection, and injected intravenously 30 minutes before treatment. The administration time should exceed 5 minutes. Most patients only need to take the drug once, and the prevention effect on nausea and vomiting can last for more than 24 hours. If necessary, the number of administrations can be increased by 1-2 times, but the maximum daily dose should not exceed 9 mg. The elderly and those with liver and kidney dysfunction do not need to adjust the dose.

Common side effects include headache, fatigue, fever, constipation, and occasional transient asymptomatic elevation of liver transaminases. These reactions are mild and do not require special treatment.

1. Patients who are allergic to this product or related compounds are prohibited from using this product. 2. Patients with gastrointestinal obstruction are prohibited from using this product.

Precautions for children: The recommended dose for children aged 2 to 16 is 10 μg/kg; the use of this drug for children under 2 years old is not yet clear. Precautions for pregnancy and lactation: 1. Pregnant women should not use this drug unless necessary. 2. Lactating women should use this drug with caution. If using this drug, breastfeeding should be stopped.

1Granisetron does not induce or inhibit the cytochrome P-450 drug metabolizing enzyme system. 2Because granisetron is metabolized by the hepatic cytochrome P-450 drug metabolizing enzyme, induction or inhibition of this enzyme could alter the clearance rate and half-life of granisetron.

Keep in a dark place and sealed. Valid for 24 months.

3 ml: 3 mg (based on C18H24N4O)

24 months

Qilu Pharmaceutical Co., Ltd.

• Founded in:

  1992-08-21

• Address:

  No. 317, Xinluo Street, High-tech Zone, Jinan City, Shandong Province

• Tax NO.:

  91370000614073351Q

• Registered Funds:

  600 million yuan

• Website:

  Log in to view

• Email:

  Log in to view